CD274 and esophageal squamous cell carcinoma: Ipilimumab (YERVOY) is recommended as the first-line treatment combined with nivolumab (OPDIVO) among patients with advanced melanoma, RCC, unresectable MPM, metastatic NSCLC expressing PD-L1 (≥1%) and unresectable advanced or metastatic ESCC.